Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Debt to Equity (2023 - 2025)

Perspective Therapeutics' Debt to Equity history spans 3 years, with the latest figure at $0.01 for Q3 2025.

  • For Q3 2025, Debt to Equity rose 31.06% year-over-year to $0.01; the TTM value through Sep 2025 reached $0.01, up 31.06%, while the annual FY2024 figure was $0.01, 74.92% down from the prior year.
  • Debt to Equity for Q3 2025 was $0.01 at Perspective Therapeutics, up from $0.01 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.02 in Q4 2023 and bottomed at $0.0 in Q2 2024.
  • The 3-year median for Debt to Equity is $0.01 (2025), against an average of $0.01.
  • The largest annual shift saw Debt to Equity crashed 74.92% in 2024 before it surged 31.06% in 2025.
  • A 3-year view of Debt to Equity shows it stood at $0.02 in 2023, then crashed by 74.92% to $0.01 in 2024, then grew by 16.9% to $0.01 in 2025.
  • Per Business Quant, the three most recent readings for CATX's Debt to Equity are $0.01 (Q3 2025), $0.01 (Q2 2025), and $0.01 (Q1 2025).